Explanipedia

Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy Open

Marshall Winget, Hunter Sowell, Kendall C. Shultes, Jana Sawyer, Reena Jayani , et al. · 2025

CD-19 chimeric antigen receptor T-cell therapy (CAR-T) has improved outcomes in relapsed/refractory B-cell malignancies but is associated with cytokine-mediated toxicities such as cytokine release syndrome (CRS), immune effector cell-assoc…

161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM Open

Swetha Kambhampati, Liangyi Chen, Sairah Ahmed, Allison M. Bock, Narendranath Epperla , et al. · 2025

566 | REAL‐WORLD OUTCOMES OF MOSUNETUZUMAB USE FROM THE CUBIC CONSORTIUM Open

Andrew Jallouk, Lei Feng, Amy Ayers, Amrita Chauhan, Swetha Kambhampati , et al. · 2025

243 | REAL‐WORLD OUTCOMES OF CD20xCD3 BISPECIFIC ANTIBODY THERAPY IN ADULT PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED INDOLENT LYMPHOMA Open

P. Stéphan, Karan Chohan, Robert Redd, Saira Ahmed, Christopher R. Flowers , et al. · 2025

667 | REAL‐WORLD SAFETY AND EFFICACY OF EPCORITAMAB FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS Open

Allison M. Bock, Lei Feng, Amy Ayers, Amrita Chauhan, Swetha Kambhampati , et al. · 2025

Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial Open

Bhagirathbhai Dholaria, Shakthi Bhaskar, Vivek Patel, Eden Biltibo, Reena Jayani , et al. · 2025

The pivotal trials of axicabtagene ciloleucel (axi-cel) chimeric Antigen receptor (CAR-T) therapy and other CD19 CAR-Ts were mainly done in the inpatient setting. We conducted a single-center non-randomized open label prospective clinical …

Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease Open

Rahul Shah, Danielle Murphy, Melissa Logue, James H. Jerkins, Andrew Jallouk , et al. · 2024

Chronic graft-versus-host disease (cGVHD) represents a common long-term complication after allogeneic hematopoietic stem cell transplantation (HSCT). It imposes a significant morbidity burden and is the leading cause of non-relapse mortali…

Allogeneic and other innovative chimeric antigen receptor platforms Open

Andrew Jallouk, Salyka Sengsayadeth, Bipin N. Savani, Bhagirathbhai Dholaria, Olalekan O. Oluwole · 2024

Evaluating Antibiotic De-escalation for Autologous Stem Cell Transplant Patients With Febrile Neutropenia in a Real-World Clinical Setting Open

Marshall Winget, Katie S. Gatwood, Reena Jayani, Eden Biltibo, Andrew Jallouk , et al. · 2024

Febrile neutropenia (FN) is a complication in approximately 90% of autologous stem cell transplant (SCT) patients. Guidelines support early broad-spectrum antibiotics (BSA) to prevent morbidity and mortality. However, in patients who are c…

Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy Open

Andrew Jallouk, Naishu Kui, Ryan Sun, Jason R. Westin, Raphaël Steiner , et al. · 2023

Complications occurring after lymphodepleting chemotherapy (LDC) may delay chimeric antigen receptor (CAR) T-cell infusion. The effect of these delays on clinical outcomes is unclear. We performed a retrospective analysis of 240 patients w…

Characterization of Lymphopenia during Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Patients with Aggressive B Cell Lymphomas Open

Gohar Manzar, Susan Wu, Stephanie O. Dudzinski, Michael K. Rooney, Andrew Jallouk , et al. · 2023

A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma Open

Paolo Strati, Andrew Jallouk, Qing Deng, Xubin Li, Lei Feng , et al. · 2023

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV Open

Paolo Strati, Oren Pasvolsky, Lei Feng, Guofan Xu, Sanjit O. Tewari , et al. · 2023

2][3][4][5][6] However, the optimal management for patients who achieve a partial response (PR) remains debated.In a recently published retrospective registry study, 222 patients with LBCL who received ASCT in PR were compared with 126 pat…

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response Open

Andrew Jallouk, Sushanth Gouni, Jason R. Westin, Lei Feng, Haleigh Mistry , et al. · 2022

SD/PD (N=142) PR (N=41) CMR (N=13) P value CMR vs. SD/PD P value CMR vs. PR DLBCL/HGBCL, N (%) 105 (74) 29 (71) 10 (77) 0.814 0.664 Age in years, median (range) 59 (21-85) 61 (18-78) 53 (39-72) 0.446 0.485 Male, N (%) 92 (65) 29 (71) 7 (54…

Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy Open

Paolo Strati, Andrew Jallouk, Ryan Sun, Jaihee Choi, Kaberi Das , et al. · 2022

Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer Open

Andrew Jallouk, Sriram S. Paravastu, Katherine N. Weilbaecher, Rebecca Aft · 2021

Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis Open

Rohun U Palekar, Andrew Jallouk, Jacob W. Myerson, Hua Pan, Samuel A. Wickline · 2016

Objective— A role for thrombin in the pathogenesis of atherosclerosis has been suggested through clinical and experimental studies revealing a critical link between the coagulation system and inflammation. Although approved drugs for inhib…

Molecular Imaging of Atherosclerosis with Nanoparticle-Based Fluorinated MRI Contrast Agents Open

Rohun U Palekar, Andrew Jallouk, Gregory M. Lanza, Hua Pan, Samuel A. Wickline · 2015

As atherosclerosis remains one of the most prevalent causes of patient mortality, the ability to diagnose early signs of plaque rupture and thrombosis represents a significant clinical need. With recent advances in nanotechnology, it is no…

Quantifying progression and regression of thrombotic risk in experimental atherosclerosis Open

Rohun U Palekar, Andrew Jallouk, Matthew Goette, Junjie Chen, Jacob W. Myerson , et al. · 2015

Currently, there are no generally applicable noninvasive methods for defining the relationship between atherosclerotic vascular damage and risk of focal thrombosis. Herein, we demonstrate methods to delineate the progression and regression…

Andrew Jallouk YOU? Author Swipe